APC Anti-TMS1/ASC antibody [EPR10403],Abcam,AB320167

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Host

Rabbit

Reactivity

Human

Application

Antibody Labelling, Flow Cyt (Intra), ICC/IF, Target Binding Affinity

Conjugate

APC

Platform ID

BAB587329884

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAPC Anti-TMS1/ASC antibody [EPR10403]
Cat. No.AB320167
HostRabbit
IsotypeIgG
ReactivityHuman
ConjugationAPC
ApplicationAntibody Labelling, Flow Cyt (Intra), ICC/IF, Target Binding Affinity
ClonalityMonoclonal
Clone NumberEPR10403
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Functions as a key mediator in apoptosis and inflammation (PubMed : 11103777, PubMed : 12646168, PubMed : 15030775, PubMed : 17349957, PubMed : 17599095, PubMed : 19158675, PubMed : 19158676, PubMed : 19234215, PubMed : 19494289, PubMed : 21487011, PubMed : 24630722, PubMed : 25847972, PubMed : 30674671, PubMed : 34678144, PubMed : 36050480). Promotes caspase-mediated apoptosis involving predominantly caspase-8 and also caspase-9 in a probable cell type-specific manner (PubMed : 11103777, PubMed : 12646168). Involved in activation of the mitochondrial apoptotic pathway, promotes caspase-8-dependent proteolytic maturation of BID independently of FADD in certain cell types and also mediates mitochondrial translocation of BAX and activates BAX-dependent apoptosis coupled to activation of caspase-9, -2 and -3 (PubMed : 14730312, PubMed : 16964285). Involved in innate immune response by acting as an integral adapter in the assembly of various inflammasomes (NLRP1, NLRP2, NLRP3, NLRP6, AIM2 and probably IFI16) which recruit and activate caspase-1 leading to processing and secretion of pro-inflammatory cytokines (PubMed : 15030775, PubMed : 16982856, PubMed : 17349957, PubMed : 17599095, PubMed : 19158675, PubMed : 19158676, PubMed : 19234215, PubMed : 21487011, PubMed : 23530044, PubMed : 24630722, PubMed : 25847972, PubMed : 29440442, PubMed : 30674671, PubMed : 33980849, PubMed : 34678144, PubMed : 34706239). Caspase-1-dependent inflammation leads to macrophage pyroptosis, a form of cell death (PubMed : 24630722). The function as activating adapter in different types of inflammasomes is mediated by the pyrin and CARD domains and their homotypic interactions (PubMed : 14499617, PubMed : 19234215, PubMed : 24630722). Clustered PYCARD nucleates the formation of caspase-1 filaments through the interaction of their respective CARD domains, acting as a platform for of caspase-1 polymerization (PubMed : 24630722). In the NLRP1 and NLRC4 inflammasomes seems not be required but facilitates the processing of procaspase-1 (PubMed : 17349957). In cooperation with NOD2 involved in an inflammasome activated by bacterial muramyl dipeptide leading to caspase-1 activation (PubMed : 16964285). May be involved in RIGI-triggered pro-inflammatory responses and inflammasome activation (PubMed : 19915568). In collaboration with AIM2 which detects cytosolic double-stranded DNA may also be involved in a caspase-1-independent cell death that involves caspase-8 (PubMed : 19158675, PubMed : 19158676). In adaptive immunity may be involved in maturation of dendritic cells to stimulate T-cell immunity and in cytoskeletal rearrangements coupled to chemotaxis and antigen uptake may be involved in post-transcriptional regulation of the guanine nucleotide exchange factor DOCK2; the latter function is proposed to involve the nuclear form (PubMed : 22732093). Also involved in transcriptional activation of cytokines and chemokines independent of the inflammasome; this function may involve AP-1, NF-kappa-B, MAPK and caspase-8 signaling pathways (PubMed : 12486103, PubMed : 16585594). For regulation of NF-kappa-B activating and inhibiting functions have been reported (PubMed : 12486103). Modulates NF-kappa-B induction at the level of the IKK complex by inhibiting kinase activity of CHUK and IKBK (PubMed : 12486103, PubMed : 16585594). Proposed to compete with RIPK2 for association with CASP1 thereby down-regulating CASP1-mediated RIPK2-dependent NF-kappa-B activation and activating interleukin-1 beta processing (PubMed : 16585594). Modulates host resistance to DNA virus infection, probably by inducing the cleavage of and inactivating CGAS in presence of cytoplasmic double-stranded DNA (PubMed : 28314590).. Isoform 2. May have a regulating effect on the function as inflammasome adapter.. Isoform 3. Seems to inhibit inflammasome-mediated maturation of interleukin-1 beta. See full target information PYCARD

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.